Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00126269|
Recruitment Status : Unknown
Verified September 2006 by Gustave Roussy, Cancer Campus, Grand Paris.
Recruitment status was: Recruiting
First Posted : August 3, 2005
Last Update Posted : September 8, 2006
This is a randomized phase III trial comparing cisplatin with or without gemcitabine in patients with carcinoma of unknown primary and a predicted favorable prognosis.
The purpose of this trial is to compare the overall survival rates of patients with carcinoma of unknown primary (CUP) and a predicted favorable prognosis according to the French classification treated with cisplatin with or without gemcitabine.
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma||Drug: cisplatin Drug: gemcitabine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||192 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Phase III Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary and a Predicted Favorable Prognosis|
|Study Start Date :||May 2003|
- Overall survival
- Response rate
- Progression-free survival
- Quality of life
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00126269
|Contact: Karim FIZAZI, Dr||33 1 firstname.lastname@example.org|
|Institut Gustave Roussy||Recruiting|
|Villejuif, France, 94805|
|Contact: Karim FIZAZI, Dr 33 1 42114559 email@example.com|
|Principal Investigator:||Karim FIZAZI, Dr||Gustave Roussy, Cancer Campus, Grand Paris|